Selcita Tablet 50 mg (Sitagliptin Hydrochloride Hydrate)
Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.
MFDS item code 202005877 · Approved 2020.08.18
This product's status changed to Expired on 2025.08.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to help control blood sugar levels in patients with type 2 diabetes. It can be administered alone or in combination with dietary and exercise therapy, and can also be used alongside metformin for those starting diabetes medication for the first time. If blood sugar control is difficult due to monotherapy with sulfonylureas, metformin, thiazolidinediones, or insulin, this medication can be added to enhance effectiveness. Additionally, it can be added to treatment regimens that are insufficient for blood sugar control. Therefore, this medication aids in improving blood sugar control in patients with type 2 diabetes.
Administer 100mg once daily as monotherapy or combination therapy; the maximum daily dose is 100mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before starting this medicine and periodically during treatment. 1. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). Administer this medicine regardless of the timing of dialysis.
This medication is used for diabetes treatment, and severe allergic reactions may occur during use, requiring caution. If symptoms of hypersensitivity such as skin rash, angioedema, or difficulty breathing occur within 3 months of starting the medication, it should be discontinued immediately and a doctor should be consulted. Additionally, serious side effects including acute pancreatitis have been reported; therefore, if symptoms such as abdominal pain, nausea, or vomiting occur during use, medical personnel should be notified immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and should not be administered if there is an allergy to the drug or its components. Patients with impaired renal function may have difficulty excreting the medication, requiring dose adjustments, and it is recommended to have regular kidney function tests. Hypoglycemic symptoms may occur during treatment, especially when used in conjunction with insulin or sulfonylureas, increasing the risk, so blood sugar levels should be monitored closely. Furthermore, severe joint pain or skin blistering may occur after medication administration; if such symptoms are present, the physician should be notified immediately. Women who are pregnant or breastfeeding are advised not to use this medication due to uncertain safety. Elderly patients may have reduced kidney function, necessitating dose adjustments and kidney function tests. In case of overdose, general emergency treatment should be administered, and some of the drug may be removed via hemodialysis if necessary. This medication may increase the risk of hypoglycemia when used in combination with other hypoglycemic agents, so dose adjustment may be necessary when combined. Drug interactions are relatively rare; however, it is advisable to consult a doctor when taking certain medications. If there are any unusual symptoms or suspected side effects during use, immediate consultation with medical personnel is required.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to prevent air or moisture ingress, and keep it at room temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the effectiveness and safety of the drug.
Light orange, round, biconvex film-coated tablet
28 tablets (14 tablets/PTP x 2) - 14 tablets/PTP [28 tablets (14 tablets/PTP x 2)], 30 tablets (10 tablets/PTP x 3) - 10 tablets/PTP [30 tablets (10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.